Antiretroviral therapy allows a restoration of immune cell homeostasis associated with a normal immune competence. Our goal was to analyze the modulation of polyfunctional HIV-specific CD8+ T-cell responses during antiretroviral therapy. HIV-infected individuals were divided into four groups according to CD4+ cell count and viral load at the moment of recruitment. Whole blood was stimulated with a pool of CD8-specific HIV-antigens to assess cytokine/chemokine production and cytotoxicity activity by using flow cytometry. The groups show different modulation in HIV-specific CD8+ T-cell responses. In particular, immunological failure showed different distributions of polyfunctional HIVspecific CD8+ responses, mainly due to an increase of cells producing CDI07a/IFNy/lL-2/MIP-lp. Our results indicate that this particular 4+ functional subset is a possible correlate of immunological failure. Considering the complexity of interactions among HAART, immune system and HI~work is in progress to find correlates of therapy efficacy.
During the acute phase of HIV infection, a partial control of viral replication is associated with a marked expansion of virus-specific CD8+ T cells (1, 2), indicating that CD8+ T cell responses may play an important role in controlling HIV replication. Initiation of antiretrovira1 therapy (HAART) has multiple effects on the immune system, including a reduction of generalized immune activation and the reconstitution of peripheral CD4+ T cells (3) (4) (5) (6) (7) . Increasing evidence suggests that qualitative rather than quantitative aspects of CD8+ T-cell immunity provide the key to antiviral efficacy (8, 9) . Despite intense efforts, however, the precise attributes that confer certain CD8+ T-cell populations an advantage in controlling HIV remains unclear. CD8+ T cells are capable of multiple functions, including cytolysis and cytokine/chemokine production. Therefore, measurement of only one or two CD8+ T-cell functions may not provide an adequate measure of CD8+ T-cell response quality. Recent technologic advancements in flow cytometry now permit the simultaneous examination of multiple T-cell functions (10, 11) . Polyfunctional T lymphocytes are present at high frequency in the blood of patients who spontaneously control virus replication ("Long Term Non-Progressors" (LTNP) and "elite controllers") (12) (13) (14) (15) . The aim of our work was to analyze the modulation of polyfunctional HIV-specific CD8+ T-cell responses during antiretroviral therapy in four-HIV+ patient groups differing in CD4 cell count and viral load at the moment of recruitment.
Specifically, we used polychromatic flow cytometry to assess simultaneously five CD8+ T-cell functions, including degranulation (CD I07a) and cytokine (INFy, TNF-a, and IL-2) and chemokine production (MIP-l P). Our findings indicate that progressor and immunological non-responder patients, both failing in immunological recovery, showed different distributions of polyfunctional HIV-specific CD8 responses, mainly due to an increase of cells producing simultaneously CDI07a, IFNy, IL-2, and MIP-lp.
MATERIALS AND METHODS

Study patients
HAART-treated HIV+ patients (63) of both genders (range: 25-64 years), recruited from the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome, were divided into four different groups according to CD4+ cell count and viral load (VL) at the moment of recruitment: Responder (R, n=14) (CD4+ counts >700 cells/ul., range: 722-1836; undetectable (NR) VL); Progressor (P, n=17) (CD4+ counts <200 cells/ ul., range: 3-178; VL > 1000 copies/uL, range: 1143-3057369); Immunological Non-Responder (INR, n= 18) (CD4+ counts <200 cells/ul., range: 41-165; NR VL or <200 copies/ul., range: NR-107); and Virological Non-Responder (VNR, n=14) (CD4+ counts >300 cells/ul.: range: 319-1285; VL >3000 copies/ul.: range: 3112-327986). Anonymised residual samples for routine CD4+ analysis were used for the study. The study was endorsed by the local Ethics Committee.
Stimulation ofwhole blood andflow cytometry analysis
CDI07a, IFNy, IL-2, MIP-l~, and TNF-a expression were simultaneously examined by using multiparametric flow cytometry in response to a pool of HIV peptides (NIH/AIDS Reagent Program, Germantown, MD, USA) and to peptides derived from cytomegalovirus, Epstein-Barr virus and influenza virus (CEF). The HIV-peptides were specifically designed for CD8 T-cell response. Briefly, whole blood was stimulated with the HIVpeptide pool, CEF (2 ug/ml.), or with PMA/Ionomycin as positive control. The CDI07a-PE-Cy5 antibody was added at the initiation of culture. Brefeldin A (50 ug/rnl.) was added after antigen stimulation. After staining with surface antibodies anti -CD45-Amcyan, -CD8-APC-H7, and -CD4-Pacific blue (10 min at 4°C), a lysing/fixing solution was added to the cells, according to manufacturer instructions (Becton-Dickinson BD, Buccinasco, Milano, Italy). After washing (PBS/BSAlNaN 3 buffer), cells were incubated with antibodies for intracellular staining (anti -TNF-a-FITC, -MIP-l~-PE, -IL-2-APC and IFNy-PE-Cy7) (20 min at room temperature (RT» prepared using a 0.5%/saponin solution, and then washed with 0.1%/ saponinlPBS/BSAlNaN 3 solution. All antibodies were purchased from BD (Buccinasco, Milano, Italy) while TNF-a and IL-2 from Miltenyi Biotec (Calderara di Reno Bologna, Italy). Samples were acquired on FACSCanto II (BD, Buccinasco, Milano, Italy) flow/cytometer and analyzed using FlowJo 6.4.7 software (TreeStar, Olten, Switzerland). Fig. lA shows the gating strategy used. After background correction, SPICE Software was used to graph response data (16) .
Statistical analysis
The comparison between functional profiles of the study groups was performed using the Mann-Whitney test applying the Bonferroni adjustment of P-values for multiple testing. For each functional profile analyzed, the contribution to the global CD8+ response, expressed as the proportion of the global response due to each subset, was calculated. The contribution of each subset were expressed as median (lQR).
RESULTS
High viral load induces higher total response
In four groups of long-term HAART-treated patients (R, P, INR and VNR), differing in CD4+ cell count and VL, we evaluated the magnitude and quality of the specific response of CD8+ T lymphocytes to a pool of HIV-viral antigens derived from Gag, Nef and Tat.
An immunological gating was done on CD45+ cells, followed by a forward/side scatter-gating on lymphocytes, and finally, a gate on bright CD8+ T cells. Within CD8+ T cells, a gate was made for each respective function using combinations that provided optimal separation ( Fig. lA) . Boolean gate platform was used to create the full array of possible combinations of response patterns when testing five functions (31 except all negative, 2°-1).
We have analyzed the "total" response, defined as the sum of all cells positive for at least one function (CDI07a, IFNy, IL-2, MIP-1P orTNF-a), as a tool to provide a view ofthe overall frequency ofresponding cells among CD8+ T lymphocytes. As shown in 
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Fig. 5. CD8+ unique subset responses against CMV-, EBV-and influenza virus-specific antigen (CEF). The colored graphs show median and inter-quartile range (box plot), and vertical lines show the minimum and maximum values of multiple CD8+ cell subpopulations expressing the particular combination of functions in response to
CEFfor each group ofpatients. Each + denotes CDI 07a, IFNy, IL-2, MIP-I{J and/or TNF-a positivity. **p<0.008 comparing the groups. Differences between groups were assessed using the Mann-Whitney test applying Bonferroni adjustment of P-values for multiple testing (p<0.008for 4 parameters testing).
maintaining a higher HIV-specific response (17, 18) . 
4+ functional subset contributes mostly in patients with high viral load
We then evaluated the contribution to the total response of CD8+ subsets according to the number of functions (5+, 4+ 3+ 2+ or 1+) and found that Rand P groups displayed a significantly different global profile (p<O.008) ( Fig. 2A) . Moreover, as shown in Fig. 2B , we found that the 4+ CD8+/subset was the most represented in P and VNR groups if compared to the R group (p<O.008). These data suggest that viral load influence the contribution of different subsets in responding to HIV antigens in terms of number of functions.
The CD8+ functional subset expressing CD107a/ IFNy/IL-2/MIP-I{J changes according to CD4+ cell count
We analyzed the contribution of the 31 functional PieSike combinations to the total HIV-specific CD8+ response (Fig. 3) . Specifically, we found that the CD8+ functional subset expressing CD107a/IFNy/ IL-2/MIP-l~was significantly higher in P and INR compared to the R group (p<O.008). The remaining functional subsets were comparable among study groups. These results suggest that CD4+ cell count could affect the capability of CD8+ T cells to produce simultaneously CD107a, IFNy, IL-2 and MIP-l~. Moreover, the global functional profile appeared significantly different in P and in INR groups compared to R group (p<O.008, Fig. 4 ).
In summary, our results suggest that virological failure during HAART is associated with an HIVspecific CD8+ T-cell4+ response, while immunologic failure is associated with an HIV-specific CD8+ functional subset expressing CDI07a/IFNy/IL-2/ MIP-l~.
Effect ofantiretroviral therapy on CMV-, EB Vand influenza virus-specific CD8+ T-cell response
In all groups, CEF-specific CTL response was also analyzed. The level of total (data not shown) and specific individual (Fig. 5 ) functional responses among CD8 T cell did not change significantly after comparing the groups. These data suggest a modulation of CD8+ responses only toward specific HIV antigens.
DISCUSSION
Viral antigen has been associated with both the development and the proliferation of virus-specific CD8+ T cells during acute infection, and their functional impairment has been found in the setting of persistent antigenaemia during chronic viral infection (19) . During HIV infection, the initiation of antiretroviral therapy has multiple effects on the immune system, including the reduction of generalized immune activation and the partial reconstitution ofperipheral CD4+ T cells (3) (4) (5) which could potentially influence, and possibly improve, HIV-specific CD8+ T-cell functionality.
The identification of a CD8+ T-cell correlate of immune control in HIV infection has remained an elusive, yet profoundly important goal that could improve immunotherapeutic strategies. However, the heterogeneity that exists between individuals and between CD8+ T-cell populations represents a major barrier to the precise identification of these attributes. To date, there are few cross-sectional studies analyzing CD8+ T-cell response during antiretroviral therapy, most of which consider naive treatment patients or analyze CD8+ T-cell response before and after therapy.
Our goal was to describe polyfunctional CD8 specific response of HIV+ patients during HAART for the identification of variations associated to treatment outcome. CD8-HIV specific total response was driven, during antiretroviral therapy, by HIV-RNA level, with the highest response in patients with high viral load and extremely low in patient with low viral load. This result is in line with others (17, 18) in reporting decay kinetics of CTL T lymphocytes after antiretroviral therapy continuing while viremia remains undetectable.
When we analyzed the capacity ofCD8+ T cells to produce more cytokines simultaneously after antigen stimulation, we found that the CD8+ functional subset expressing four functions contributes mostly in the P and VNR groups, suggesting a role ofplasma viremia in regulating not only the total response but also the quality of the responses. Interestingly, the analysis of the ability of HIV-specific CD8 T cells to execute multiple effector functions revealed that the functional subset CD 107a/IFNy/IL-2/MIP-l WCD8 T-cells is associated with immunological failure, confirming the role of CD4+ T cells in modulating CD8+ T-cell functions. Finally, the apparent conflict between the results obtained by analyzing the whole four-cytokine response (Fig. 2B ) and the peculiar CD107a/IFNy/IL-2/MIP-IWCD8 subset may be explained by the effect of adding all the 4+ response in comparison to analyzing a single combination.
Contrasting data have been reported regarding antiretroviral therapy and polyfunctionality: some studies sustain that antiretroviral therapy does not restore polyfunctionality (20) , others (15, 21) clearly demonstrated that the quality of HIV-specific CD8+ T-cells changes fundamentally during successful HAART, increasing their functional repertoire and becoming polyfunctional. Other studies have demonstrated that recovery ofimmune responsiveness during administration of therapy is reflected in functional improvement of T-cell responses toward various recall antigens and other pathogens, however, reconstitution of fully functional, proliferative, HIVspecific CD8+ and CD4+ T-cell responses remains incomplete (20, 22) . These findings are in line with the data by Migueles et al. (20) that show a profound difference in polyfunctionality between LTNP and HAART-treated responding patients.
In summary, our results provide an unprecedented assessment of the functionality of HIV-specific CD8+ T cells in antiretroviral-treated HIV-infected individuals differing in CD4+ cell counts and viremia control. By showing that HIV-infected individuals with high CD4+ counts and undetectable viral load possess a different global functional profile when compared to HIV patients with low CD4 counts and high viremia, our results suggest that the quality of HIV-specific CD8+ T cells could be a clinical correlate of disease progression. In particular, we identified a CD8 4+ functional subset expressing CDl 07a/IFNy/IL-2/MIP-l~as a possible correlate of immunological failure. Although CDl07a, IFNy, IL-2, and MIP-l~are considered pivotal in controlling HIV replication (23) , our data suggest that, during HAART, the presence of HIV specific CD8+ T cells simultaneously producing these cytokines is not associated with the control of viremia, indicating that the complexity of interactions between HAART, immune system and HIV needs deeper investigations. These findings may be crucial to better understand the mechanisms involved in the control of disease progression during therapy, and to find correlates of therapy efficacy.
